The company will demonstrate how its products can be formulated into example nutraceutical products
At CPhI Worldwide, Omya will present its range mineral excipients for pharmaceutical and nutraceutical applications. In addition to the recently launched Omyanutra 300 DC and 300 Flash for nutraceutical tablets, the company will also focus on Omyapharm, a porous mineral excipient that facilitates the production of tablets and granules prioritising compactability, mechanical stability and fast disintegration.
Omyapharm fine powder is a filler-binder for tablets in dry granulation processes, designed to improve tablet compactability while significantly reducing disintegration time, owing to the high porosity of the structured mineral. This results in harder tablets at low compression forces that quickly disintegrate, the company says.
The company will also highlight the recently launched Omyanutra 300 DC and 300 Flash, which are made of a natural mineral material. Omyanutra 300 DC is a directly compressible version of the company’s proprietary functionalised calcium carbonate excipient that comes as free-flowing granules. The 300 Flash variant comes with a superdisintegrant and is designed as an all-in-one product for manufacturers of orally and fast-disintegrating tablets.
In addition, the company will showcase its active pharmaceutical ingredients Omyapure and Omya-Cal. Both are suitable components for calcium supplementation, antacids and bone health applications.
Bone Boost is a chewable tablet concept containing Omyapure as the active ingredient, as well as vitamins K2 and D3 from the company’s distribution portfolio. B12 Flash is an orally disintegrating tablet (ODT) based on the excipient 300 Flash combined with vitamin B12, designed to reduce tiredness and fatigue, while the ActivFresh prototype contains mint oil loaded onto 300 DC, bringing oil into tablet formulations while maintaining compactability, stability and disintegration time.
During CPhI 2021, the company’s team of pharma professionals will be available to discuss further possible applications.